Table 2.
Effect of the σ1 protein agonist, compound 1(S), on EAE developmenta
| Incidence | CDI | Disease peak | Score at D14 ± 2 | Relapse duration | Mortality | |
|---|---|---|---|---|---|---|
| EAE-vehicle | 15/15 | 71.2 (±44.5) | D13 (±4) | 4.0 (±1.0) | 21 (±13.5) | 6/15 |
| EAE-1(S) 1 mg·kg−1 | 15/19 | 45.5 (±35.8)* | D16 (±6) | 1.0 (±0.5)*** | 7.5 (±17.0)* | 2/19 |
| EAE-1(S) 5 mg·kg−1 | 14/19 | 40.0 (±34.3)* | D16 (±5) | 1.5 (±0.5)*** | 7.5 (±11.0)* | 3/19 |
To evaluate the effect of compound 1(S) on EAE development, we used three different groups, EAE-vehicle, EAE-1(S) 1 mg·kg−1 and EAE-1(S) 5 mg·kg−1. Data were compiled from three independent experiments with 5–7 animals per group (n = 15–19/group). Incidence corresponds to the frequency of the new cases reaching clinical grade 2. CDI was calculated as the sum of the daily clinical scores for each mouse (Bodhankar et al., 2011). Disease peak refers to the first day of maximal clinical score. Relapse duration refers to the number of days that mice showed a clinical score ≥2. Data are presented as median ± IQR. No significant differences were observed between any of the effects of 1 mg·kg−1 and 5 mg·kg−1 compound 1(S).
P < 0.05
P < 0.0005; significantly different from the EAE-vehicle group.